CDH1 and metastatic neoplasm: Epithelial-mesenchymal transition (EMT) is a hallmark of metastatic neoplasms, including BrC, and is involved in the concurrent downregulation of epithelial markers such as E-cadherin and α-catenin, and upregulation of mesenchymal markers such as vimentin, β-catenin, and Snail.